Literature DB >> 12787733

Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus.

Sujin Lee1, Malgorzata Gierynska, Seong Kug Eo, Nelly Kuklin, Barry T Rouse.   

Abstract

The aim of our investigation was to improve the effectiveness of DNA vaccines against herpes simplex virus (HSV) infection. We chose coimmunization with DNA encoding cytokines known to emphasize components of immune defense that best correlate with immune protection. These include interferon-producing T and NK cells and the IgG2a isotype immunoglobulin. Our results show that the coadministration of plasmid DNA encoding IL-12 or IL-18 along with glycoprotein B (gB) DNA improves immune induction. Recipients of the coimmunization procedure had elevated humoral as well as IFN-gamma-producing T cell responses and showed greater resistance to vaginal challenge with a lethal dose of HSV-1. The adjuvant effects were observed when the vaccines were administered either systemically or mucosally. By most assays, the adjuvant effect of IL-18 was superior to IL-12, although gB DNA plus IL-18 failed to induce levels of immunity achieved by UV-inactivated HSV immunization. Mucosal immunization proved as an effective means of inducing systemic immunity, but was less effective than the systemic route for inducing protection from vaginal challenge. Our results also demonstrated that protection from such challenges was mainly a property of IFN-gamma. Thus, immunized IFN-gamma-/- mice remained susceptible to challenges even while generating readily measurable immune responses. The approach of using DNA vaccines combined with DNA encoding cytokines holds promise and represents a potentially useful approach for vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12787733     DOI: 10.1016/s1286-4579(03)00108-4

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  8 in total

1.  Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant.

Authors:  Noshin Kathuria; Kimberly A Kraynyak; Diane Carnathan; Michael Betts; David B Weiner; Michele A Kutzler
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

2.  Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.

Authors:  Anahit Ghochikyan; Mikayel Mkrtichyan; Dmitri Loukinov; Gregory Mamikonyan; Svetlana D Pack; Nina Movsesyan; Thomas E Ichim; David H Cribbs; Victor V Lobanenkov; Michael G Agadjanyan
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

3.  Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.

Authors:  Kimberly A Kraynyak; Michele A Kutzler; Neil J Cisper; Amir S Khan; Ruxandra Draghia-Akli; Niranjan Y Sardesal; Mark G Lewis; Jian Yan; David B Weiner
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

Review 4.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

Review 5.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

6.  Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality.

Authors:  Bobbie Ann Austin; Cassandra M James; Peter Härle; Daniel J J Carr
Journal:  Biol Proced Online       Date:  2006-06-14       Impact factor: 3.244

Review 7.  Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.

Authors:  Xiaoguang Wang; Delong Meng
Journal:  Protein Cell       Date:  2014-12-13       Impact factor: 14.870

8.  Cloning, expression and immunoassay detection of ferret IFN-gamma.

Authors:  Atsuo Ochi; Ali Danesh; Charit Seneviratne; David Banner; Mark E Devries; Thomas Rowe; Luoling Xu; Longsi Ran; Markus Czub; Steven E Bosinger; Mark J Cameron; Cheryl M Cameron; David J Kelvin
Journal:  Dev Comp Immunol       Date:  2008-01-28       Impact factor: 3.636

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.